ITALIAN TRADE AGENCY

ITA Beijing Office

NEWSLETTER

CHEMICAL & PHARMACEUTICAL
12 - 18 October 2026



China Finalizes 2026 Hydrofluorocarbon (HFC) Production Quotas for Chemical Sector
China's Ministry of Ecology and Environment has approved the second 2026 HFC production quota adjustments for 19 major chemical enterprises. Following these structural optimizations across eight provinces, the finalized 2026 HFC production quota reached 800,177 tons. This strategic reallocation ensures compliance with climate commitments while meeting downstream industrial and refrigeration market demands. **(ChemNet)**

Global Sulfur Prices Surge Toward €920 per Ton Amid Supply Disruptions
Global sulfur prices have surged nearly tenfold toward €920 per ton, up from normal levels around €90–€185, triggered by shipping disruptions in the Strait of Hormuz. Crucial for producing sulfuric acid used in copper smelting and phosphate fertilizers, the critical chemical feedstock shortage is forcing producers to curb output, threatening downstream industrial and agricultural supply chains. **(ChemNet)**

US Extends Steep Double-Digit Tariffs on Chinese Potassium Phosphates
The US Department of Commerce has ruled in its third sunset review to maintain heavy anti-dumping duties of 95.40% and countervailing rates of 109.11% on Chinese potassium phosphate salts. Crucial for specialty fertilizers and food additives, these compounding tariffs squeeze domestic Chinese exporters' margins, accelerating their strategic transition toward Southeast Asian and Middle Eastern markets. **(ChemNet)**

China Clears Multiple Innovative Drugs Under Priority Review
The National Medical Products Administration approved several domestic innovative drugs through priority review channels during the week. New therapies cover paroxysmal nocturnal hemoglobinuria, acute gouty arthritis and multiple myeloma indications. The Center For Drug Evaluation simultaneously advanced pilot programs for rare disease and cell-gene therapy pipelines. **(Xinhua)**

China Issues 2026 National Essential Medicines List Implementation Guidance
China released implementation guidance for the 2026 edition of the National Essential Medicines List. Public medical institutions are required to update formularies within two months and prioritize essential medicines in procurement and prescriptions. Integrated medical alliances will adopt dynamic formulary adjustments with annual monitoring of usage ratios. **(China Daily)**